US Stocks

Lyra Therapeutics, Inc.

Lyra Therapeutics develops and commercializes integrated drug and delivery solutions for patients with ear, nose, and throat diseases, using its XTreo technology to deliver medicines directly to the affected tissue with a single administration. The platform has produced product candidates such as LYR-210, an anti-inflammatory implantable drug for the treatment of chronic rhinosinusitis, currently undergoing Phase II clinical trials, and LYR-220, for patients with and without nasal polyps. Founded in 2005 and headquartered in Watertown, Massachusetts, the company was known as 480 Biomedical, Inc. prior to July 2018.